CRISPR Therapeutics AG — Director's Dealing 2016

Oct 26, 2016

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: CRISPR Therapeutics AG (CRSP)
CIK: 0001674416
Period of Report: 2016-10-24

Reporting Person: George Simeon (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2016-10-24	Common Shares	C	2942560	—	Acquired	2942560	Indirect
2016-10-24	Common Shares	C	211567	—	Acquired	3154127	Indirect
2016-10-24	Common Shares	P	66500	$14.00	Acquired	3220627	Indirect

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2016-10-24	Series A-3 Preferred Shares	$	C	2942560	Disposed		Common Shares (2942560)	Indirect
2016-10-24	Series B Preferred Shares	$	C	211567	Disposed		Common Shares (211567)	Indirect

Footnotes

F1: On October 24, 2016, S.R. One, Limited ("S.R. One") acquired 66,500 common shares of the Issuer ("Common Shares") at a price of $14.00 per share in connection with the Issuer's initial public offering.

F2: These shares are held of record by S.R. One, Limited, an indirect, wholly-owned subsidiary of GlaxoSmithKline plc. Simeon J. George (the "Reporting Person") is a Vice President at S.R. One, Limited and an employee of GlaxoSmithKline LLC, an indirect, wholly-owned subsidiary of GlaxoSmithKline plc. The Reporting Person disclaims beneficial ownership of all the shares herein and this report shall not be deemed an admission of beneficial ownership of such shares for the purposes of Section 16 or for any other purpose except to the extent of his proportionate pecuniary interest therein, if any.

F3: On October 24, 2016, the Series A-3 Preferred Shares and the Series B Preferred Shares converted automatically into Common Shares on a one-for-one basis, upon closing of the Issuer's initial public offering

F4: Not applicable.